Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Setting a standard for venous thromboembolism prophylaxis.

A G Turpie1

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada. turpiea@mcmaster.ca

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|November 22, 2001
PubMed
Summary

Fondaparinux sodium significantly reduces venous thromboembolism (VTE) risk by 50% in orthopedic surgery patients compared to enoxaparin. This novel antithrombotic agent demonstrates a favorable safety profile for VTE prevention in major orthopedic procedures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Low-molecular-weight heparin: from the bench to the orthopedic patient.

Orthopedics·2014
Same author

Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge.

Orthopedics·2014
Same author

Prevention and treatment of venous thromboembolism--International Consensus Statement.

International angiology : a journal of the International Union of Angiology·2014
Same author

The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study.

Journal of thrombosis and haemostasis : JTH·2009
Same author

An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.

Journal of thrombosis and haemostasis : JTH·2008

Area of Science:

  • Pharmacology
  • Vascular Surgery
  • Orthopedic Surgery

Background:

  • Venous thromboembolism (VTE) is a significant risk following major orthopedic surgery.
  • Existing prophylactic anticoagulants like enoxaparin have established efficacy but may have limitations.
  • Novel antithrombotic agents are needed to improve VTE prevention in high-risk surgical populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of fondaparinux sodium for VTE prevention in patients undergoing major orthopedic surgery.
  • To compare fondaparinux sodium with enoxaparin, a standard anticoagulant, in preventing VTE.
  • To assess dose-dependency and specific regimens in Phase II and III trials.

Main Methods:

  • Four multicenter, randomized, double-blind, comparative Phase III trials (Ephesus, Pentathlon 2000, PentaMaks, Penthifra) were conducted.

Related Experiment Videos

  • Fondaparinux sodium (2.5 mg s.c. once daily) was compared against two enoxaparin regimens.
  • Primary efficacy endpoint: VTE occurrence by day 11. Main safety outcome: major bleeding events. 7344 patients were randomized.

    • Main Results:

    • Fondaparinux sodium demonstrated a 50% reduction in the risk of VTE compared to enoxaparin.
    • Phase II studies showed significant, dose-dependent reductions in VTE frequency.
    • Safety profiles, including clinically relevant bleeding, were similar between fondaparinux sodium and enoxaparin.

    Conclusions:

    • Fondaparinux sodium is an effective antithrombotic agent for preventing VTE in patients undergoing major orthopedic surgery.
    • The drug offers a favorable safety profile comparable to enoxaparin.
    • Fondaparinux sodium represents a valuable therapeutic option for VTE prophylaxis in this patient cohort.